Among all the RTK alterations, epidermal growth factor receptor (EGFR) gene amplification is the most common variation (approximately 40%) in GBM, although EGFR inhibitors (e.g., gefinitib and erlotinib) have not caused clinical effects in patients with GBMs in clinical trials[5]. Here, EGFR is linked to glioblastoma.